RxDoctor Payments Data

Daniel Arrison, MD

Urology · Bel Air, MDNPI 1699727370

Payments from drug & device makers

$8,590in general payments, 2019–2025

Across 389 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$869
  • Astellas Pharma US Inc$853
  • Sumitomo Pharma America, Inc.$776
  • Johnson & Johnson$730
  • Bayer$453
  • Antares Pharma, Inc.$328
  • plus $5K from 50 others

What the payments were for

  • Speaking & faculty fees$1121%
  • Travel & lodging$150%
  • Food & beverage$8,42598%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,590 in reported general payments places this provider in the 65th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$458,639
Medicare patients
1,265
Services billed
18,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide20$286,825
MyrbetriqMirabegron119$133,184
GemtesaVibegron21$26,878
Testosterone28$16,309
Tolterodine Tartrate ErTolterodine Tartrate43$6,979
Trospium Chloride ErTrospium Chloride30$6,466
Tamsulosin Hcl411$6,453
Oxybutynin Chloride ErOxybutynin Chloride127$4,251
Solifenacin Succinate51$3,940
Potassium Citrate ErPotassium Citrate36$3,345
Finasteride157$3,093
Alfuzosin Hcl ErAlfuzosin Hcl79$2,084
Estradiol20$1,802
Fesoterodine Fumarate ErFesoterodine Fumarate11$825
Testosterone Cypionate15$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$730$286,82520 claims
Astellas Pharma US IncMyrbetriq$853$133,184119 claims
Sumitomo Pharma America, Inc.Gemtesa$776$26,87821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 274 urology providers in Maryland.

Other urology in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →